Evaluation of Prostate Imaging Reporting and Data System Classification in the Prediction of Tumor Aggressiveness in Targeted Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy by Borkowetz, Angelika et al.
 
 
 
 
 
Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion) / 
This is a self-archiving document (published version):  
 
 
 
 
 
 
 
 
 
 
Diese Version ist verfügbar / This version is available on:  
https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-706254 
 
 
 
 
 
„Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFGgeförderten) Allianz- bzw. 
Nationallizenz frei zugänglich.“ 
 
This publication is openly accessible with the permission of the copyright owner. The permission is 
granted within a nationwide license, supported by the German Research Foundation (abbr. in German 
DFG). 
www.nationallizenzen.de/ 
 
Angelika Borkowetz, Ivan Platzek, Marieta Toma, Theresa Renner, Roman Herout, 
Martin Baunacke, Michael Laniado, Gustavo B. Baretton, Michael Froehner, Stefan 
Zastrow, Manfred P. Wirth 
Evaluation of Prostate Imaging Reporting and Data System 
Classification in the Prediction of Tumor Aggressiveness in Targeted 
Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy 
 
Erstveröffentlichung in / First published in: 
Urologia Internationalis. 2017, 99 (2), S. 177 – 185 [Zugriff am: 19.05.2020]. Karger. ISSN 1423-
0399.  
DOI: https://doi.org/10.1159/000477263     
  
E-Mail karger@karger.com
 Original Paper 
 Urol Int 2017;99:177–185 
 DOI: 10.1159/000477263 
 Evaluation of Prostate Imaging Reporting and 
Data System Classification in the Prediction of 
Tumor Aggressiveness in Targeted Magnetic 
Resonance Imaging/Ultrasound-Fusion Biopsy 
 Angelika Borkowetz  a    Ivan Platzek  b    Marieta Toma  c    Theresa Renner  a    
Roman Herout  a    Martin Baunacke  a    Michael Laniado  b    Gustavo B. Baretton  c    
Michael Froehner  a    Stefan Zastrow  a    Manfred P. Wirth  a   
 a   Department of Urology,  b   Department of Radiology and Interventional Radiology, and  c   Department of Pathology, 
Technische Universitaet Dresden,  Dresden , Germany 
rate was 43% in fusPbx ( n = 267; 34% significant PCa) and 
36% in sysPbx ( n = 223; 27% significant PCa). Nine percent-
age of significant PCa were detected by sysPbx alone. A total 
of 1,162 lesions were investigated. The detection rate of sig-
nificant PCa in lesions with PI-RADS 2, 3, 4, and 5 were 9% 
(18/206), 12% (56/450), 27% (98/358), and 61% (90/148) re-
spectively. maxPI-RADS  ≥ 4 was the strongest predictor for 
the detection of significant PCa in comPbx (OR 2.77; 95% CI 
1.81–4.24;  p < 0.005).  Conclusions: maxPI-RADS is the stron-
gest predictor for the detection of significant PCa in comPbx. 
Due to a high detection rate of additional significant PCa in 
sysPbx, fusPbx should still be combined with sysPbx. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 Multiparametric magnetic resonance imaging 
 (mpMRI) plays an increasingly important role in the 
diagnosis of prostate cancer (PCa). mpMRI detects 
clinically significant PCa with a relatively high sensitiv-
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 Abstract 
 Objectives: The study aimed to evaluate the prediction of 
Prostate Imaging Reporting and Data System (PI-RADS) with 
respect to the prostate cancer (PCa) detection rate and tu-
mor aggressiveness in magnetic resonance imaging (MRI)/
ultrasound-fusion-biopsy (fusPbx) and in systematic biopsy 
(sysPbx).  Materials and Methods: Six hundred and twenty 
five patients undergoing multiparametric MRI were investi-
gated. MRI findings were classified using PI-RADS v1 or v2. 
All patients underwent fusPbx combined with sysPbx (comP-
bx). The lesion with the highest PI-RADS was defined as max-
imum PI-RADS (maxPI-RADS). Gleason Score  ≥ 7 (3 + 4) was 
defined as significant PCa.  Results: The overall PCa detection 
rate was 51% ( n = 321; 39% significant PCa). The detection 
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ity and specificity  [1, 2] . Improved visualization of can-
cer foci and targeting of tumor-suspicious lesions by 
MRI/ultrasound-fusion biopsy (fusPbx) leads to an in-
creased detection of clinically significant PCa  [3, 4] . 
This enables a more accurate risk-stratification and 
thus, a better counseling of patients for treatment strat-
egies.
 The Prostate Imaging Reporting and Data System 
 (PI-RADS) was published in 2012 as a consensus-based 
guideline by the European Society of Urogenital Radiol-
ogy (ESUR) to standardize the evaluation and reporting 
of prostate MRI  [5] . Several studies revealed that PI-
RADS appears to have a reliable diagnostic accuracy and 
correlation with tumor aggressiveness  [6–8] . Further-
more, it shows a good inter-reader agreement  [9] . Espe-
cially lesions classified as PI-RADS 4 and 5 harbor a high 
portion of high-grade PCa  [7] .
 In 2014, the ESUR published an updated version of the 
PI-RADS classification system (PI-RDAS v2). PI-RADS 
v2 intends to represent a guideline for minimally accept-
able technical parameters of mpMRI. PI-RADS v2 aimed 
to simplify mpMRI reports and to reduce the inter-read-
er variability  [10] .
 The aim of this study was to evaluate the prediction of 
PI-RADS with respect to the tumor-detection rate and tu-
mor aggressiveness in targeted transperineal fusPbx as 
well as in combination of fusPbx and transrectal system-
atic biopsy (sysPbx). Furthermore, we assessed the value 
of PI-RADS 2 and 3 lesions for targeted biopsy and for 
combined biopsy (comPbx) with respect to the biopsy 
 results.
 Methods 
 Data were collected prospectively with the approval of the In-
stitutional Review Board of the University of Dresden (Vote: 
EK53022014). This study included only those patients who had an 
mpMRI performed and evaluated according to the START criteria 
 [11] and in whom PI-RADS could be applied.
 Patients underwent mpMRI either at the Department of Ra-
diology of our hospital or at ambulatory radiology offices. At the 
Department of Radiology of our hospital, mpMRIs were per-
formed on a 3-tesla MR system (Magnetom Verio, Siemens Med-
ical Solutions, Erlangen, Germany). A 6-channel body matrix 
coil was used in combination with the system’s integrated 
12-channel spine matrix coil for signal acquisition. The mpMRI 
protocol is shown in  Table 1 . Dynamic contrast-enhanced, time-
resolved imaging with stochastic trajectories was performed with 
75 acquisitions. The acquisition of the dynamic contrast-en-
hanced images started simultaneously with the start of an intra-
venous injection of 20 mL 0.5  M gadopentate dimeglumin 
(Magnevist, Bayer Schering Pharma, Berlin, Germany) with an 
injection rate of 2 mL/s, followed by a 20 mL flush of 0.9% saline, 
also injected with 2 mL/s. The total MRI acquisition time was 25 
min.
 All MR images were evaluated prospectively by board-certified 
radiologists with more than 10 years of experience in prostate MRI. 
Based on the criteria of ESUR  [5, 10], PI-RADS v1 or v2 was used to 
evaluate tumor-suspicious lesions. The mpMRI of patients exam-
ined before April 2015 was evaluated according to PI-RADS v1. If 
patients had an mpMRI done since April 2015, mpMRI was evalu-
ated according to PI-RADS v2. A reevaluation according to PI-
RADS v2 in mpMRIs evaluated by PI-RADS v1 and vice versa was 
not performed. Lesions classified according to PI-RADS v1 and v2 
were defined as follows: PI-RADS 1: clinically significant PCa is 
highly unlikely; PI-RADS 2: clinically significant PCa is unlikely; PI-
RADS 3: clinically significant PCa is equivocal; PI-RADS 4: clini-
cally significant PCa is likely; PI-RADS 5: clinically significant PCa 
is highly likely.
Table 1.  Sequence parameters of multiparametric MRI protocol
Parameter T1 TSE T2 TSE SS Epi DWI Dynamic 
contrast-enhanced 
TWIST
T1 TSE 
with fat 
suppression
Plane Axial Axial, sagittal Axial Axial Axial
RT/ET, ms 600/11 10,000/123 8,300/93 4.83/1.87 750/11
Field of view, mm 330 × 288 200 × 200 221 × 260 260 × 260 320 × 288
Matrix 320 × 288 320 × 320 160 × 136 192 × 192 320 × 288
Sections 39 26 26 – 39
Interslice gap, mm – – 0 – –
b-value, s/mm2 – – 0; 500; 1,000; 1,500; 2,000 – –
Section thickness, mm 5 3 3 3 5
Acquisition time, min 02:57 04:51 07:38 04:26 02:46
 TSE, turbo spin echo; TWIST, time-resolved imaging with stochastic trajectories; DWI, diffusion-weighted imaging; RT, repetition 
time; ET, echo time.
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 The BioJet-System (D&K Technologies, Barum, Germany) was 
used for fusPbx. Targeted biopsy was performed in a transperi-
neal approach while taking at least 2 cores per lesion. Lesions clas-
sified as PI-RADS  ≥ 2 were biopsied. Subsequently, every patient 
underwent a transrectal sysPbx. sysPbx was performed according 
to an in-house scheme covering 12 regions of the prostate. sysPbx 
was completed by the same urologist who had performed the tar-
geted biopsy.
 All biopsy specimens were investigated at the Department of 
Pathology of our hospital by an experienced uropathologist. We 
defined a Gleason Score (GS)  ≥ 7 (3 + 4) as significant PCa. The 
maximum PI-RADS (maxPI-RADS) in mpMRI was defined as the 
lesion with the highest PI-RADS of all lesions per patient. The in-
fluence of the maxPI-RADS for the biopsy results in comPbx was 
investigated. Furthermore, all lesions detected in mpMRI were 
evaluated based on the tumor-detection rate and GS. Lesions clas-
sified as PI-RADS 2 and PI-RADS 3 were evaluated for tumor de-
tection when these lesions existed alone or beside other lesions 
classified with a higher PI-RADS.
 Patient-based (maxPI-RADS) analysis and lesion-based (all le-
sions in mpMRI) analysis of detection rates in lesions detected in 
mpMRI were performed.
 Data were analyzed using SPSS version 23.0 (IBM Corp., Ar-
monk, NY, USA). Chi-square-test was used to determine differ-
ences between numerical and categorical variables. The McNemar 
test was employed to compare the detection rate of fusPbx to sys-
Pbx. A  p value <0.05 was considered statistically significant. Logis-
tic regression analysis was used to evaluate the prediction of max-
PI-RADS. Receiver operating characteristics (ROC) analyses, cal-
culating the area under the curve (AUC), were used to compare the 
ability to predict the detection of PCa.
 Results 
 Seven hundred and seventy five patients were evalu-
ated retrospectively. One hundred and thirty nine pa-
tients were excluded due to MRIs not fulfilling the 
START-criteria or due to incomplete imaging data set. 
In 114 of these patients, mpMRI were performed in am-
bulatory radiology offices. Eleven patients were excluded 
because of suspicion of PCa relapse after radiotherapy 
required additional biopsy or due to a performed trans-
perineal sysPbx. Finally, further investigations were 
 carried out on the remaining 625 patients. Patients’ de-
mographic details of the study cohort are depicted in 
 Table 2 .
 The overall cancer-detection rate and detection rate of 
significant PCa defined as GS  ≥ 7 (3 + 4) in comPbx, fus-
Pbx, and sysPbx are shown in  Table 3 .
 Overall ( n = 625), 31% of PCa (98/321) were detected 
in fusPbx alone; 17% of PCa (54/321) were detected in 
sysPbx alone. fusPbx alone would have detected 28% of 
significant PCa (68/246). SysPbx alone would have de-
tected 9% significant PCa (23/246). Missing rates of all 
and significant PCa by fusPbx and sysPbx in patients 
undergoing first biopsy, repeat biopsy, or control biop-
sy for active surveillance protocols are presented in 
 Table 4 .
 In patients on active surveillance undergoing control 
biopsy by comPbx, tumor upgrading to significant PCa 
occurred in 61% (22/36) of patients (in fusPbx: 74% 
[20/27]; in sysPbx: 54% [14/26];  p = 0.109).
Table 2.  Patients’ demographics, findings in mpMRI, and histopa-
thology of prostate biopsy cores
Parameter Value
Age, years, median (min; max) 66 (46; 86)
PSA, ng/mL, median (min; max) 8.17 (1; 112)
Positive findings in DRE, n 83
First biopsy, n 133
Repeat biopsy, n 445
Patients with known PCa (under active 
surveillance), n 47
Prostate volume, mL, median (min; max) 50 (12; 270)
Overall biopsy cores per patient, n (median) 19 (11; 27)
Targeted biopsy cores per patient, n (median) 7 (2; 16)
Systematic biopsy cores per patient, n (median) 12 (8; 16)
Number of lesions/patient, mean ± SD 1.9±0.9
MRI before prostate biopsy
PI-RADS v1, n 458
PI-RADS v2, n 167
mpMRI performed at 
In-house radiology department, n
Ambulatory offices, n
605
20
Total number of lesions
PI-RADS of lesion, n
2
3
4
5
1,162
206
450
358
148
maxPI-RADS in investigated patients, n
2
3
4
5
65
196
247
117
Localization of positive lesions, n (%)
Peripheral zone
Central zone
Ventral zone
Overlapping in different regions
262 (23)
119 (45)
72 (27)
68 (26)
3 (1)
Histological findings in combined prostate biopsy
Gleason Score of biopsy (combination of targeted 
and systematic biopsy), n
No tumor
3 + 3 = 6
3 + 4 = 7
4 + 3 = 7
≥8
304
75
143
37
66
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 Comparison of mpMRI to the Biopsy Results: 
A Lesion-Based Analysis 
 Figure 1 represents the overall cancer-detection rate 
and the detected GS per lesion in all patients and in sub-
groups. Especially, patients with the first biopsy showed 
higher detection rates of significant PCa in lesions classi-
fied as PI-RADS 4 and 5. Overall, the detection of signif-
icant PCa was significantly higher in lesions classified as 
PI-RADS  ≥ 4 compared to lesions classified as PI-RADS 
 ≤ 3 (37% [188/506] vs. 11% [74/656],  p < 0.005). In ROC-
analysis, the AUC of PI-RADS was 0.726 (95% CI 0.690–
0.762) for the detection of significant PCa ( Fig. 2 ). The 
sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), and accuracy for the de-
tection of significant PCa in lesions classified as PI-RADS 
 ≥ 4 was 72, 65, 37, 89, and 66%, respectively.
 Regarding only lesions classified as PI-RADS 2, 88% of 
these lesions (181/206) did not harbor PCa. Nine percent 
of PI-RADS 2 lesions showed evidence of significant PCa 
(18/206; in 17 patients). In 3% (7/206) of PI-RADS 2 le-
sions, PCa of GS 6 was detected. Thirty-three percent of 
lesions harboring significant PCa (6/18) were associated 
with another lesion with proven significant PCa. All of 
these associated lesions were classified as PI-RADS  ≥ 4. In 
total, 65 patients (10%) presented only PI-RADS 2 le-
sions. Of these patients, 11 harbored significant PCa in 
these lesions. In 6 of these patients, significant PCa was 
detected in sysPbx as well, and 5 of them did not present 
significant PCa in sysPbx. However, 6 patients with only 
PI-RADS 2 lesions lacking evidence of significant PCa 
presented a significant PCa in sysPbx. In total, 7% of sig-
nificant PCa (17/246) would not have been detected, if 
patients presenting exclusively PI-RADS 2 lesions would 
not have undergone either targeted or sysPbx.
 Regarding PI-RADS 3 lesions, 80% of these lesions 
(362/450) did not harbor PCa. 12.4% PI-RADS 3 lesions 
(56/450; 34 patients) showed evidence of significant 
PCa. In 7% (32/450) of PI-RADS 3 lesions, PCa of GS 6 
Table 3.  Detection of prostate cancer and detection rate of significant PCa defined as GS ≥7 (3 + 4) in the comPbx, fusPbx alone, and 
sysPbx alone
Detection rate of all Pca  Detection rate of significant PCa
comPbx fusPbx sysPbx p value
(fusPbx vs. 
sysPbx)¶
com Pbx fusPbx sysPbx p value
(fusPbx vs. 
sysPbx)¶
All patients (n = 625) 321 (51) 267 (43) 223 (36) <0.005 246 (39) 213 (34) 167 (27) <0.005
First biopsy (n = 133) 70 (53) 65 (49) 55 (41) 0.041 59 (44) 54 (41) 47 (35) 0.143
Repeat biopsy (n = 445) 215 (48) 175 (39) 142 (32) 0.002 165 (37) 139 (31) 106 (24) <0.005
Active surveillance (n = 47) 36 (77) 27 (57) 26 (55) 1.0 22 (47) 20 (43) 14 (30) 0.109
 The values are n (%).¶ McNemar-test.
Table 4.  Missed PCa in sysPbx and MRI/fusPbx
Indication of biopsy sysPbx  fusPbx
missed PCa (all) missed significant PCa miss ed PCa (all) missed significant PCa
All patients (n = 625) 98 (31) 68 (28) 54 (17) 23 (9)
First biopsy (n = 133) 15 (21) 9 (15) 5 (7) 3 (5)
Repeat biopsy (n = 445) 73 (34) 52 (32) 40 (19) 19 (12)
Control-biopsy for active surveillance 
protocol (n = 36) 10 (28) 7 (32) 9 (25) 1 (5)
Values are n (%).
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 Fig. 1. Detection rate and distribution of GS in lesions detected 
in mpMRI compared to the biopsy result in targeted MRI/ultra-
sound-fusPbx in all patients and in subgroup analysis. All pa-
tients ( n = 625; lesions  n = 1,162): PI-RADS 2: (25/206 [12%]; 
GS  ≥ 7:  n  = 18 [9%]), PI-RADS 3 (88/450 [20%]; GS  ≥ 7:  n = 56 
[12%]), PI-RADS 4 (118/358 [33%]; GS  ≥ 7:  n = 98 [27%]), and 
PI-RADS 5 (104/148 [70%]; GS  ≥ 7:  n = 90 [61%]). Patients un-
dergoing repeat biopsy ( n = 445; lesions  n = 846): PI-RADS 2: 
(16/155 [10%]; GS  ≥ 7:  n = 12 [8%]), PI-RADS 3 (64/345 [19%]; 
GS  ≥ 7:  n = 45 [13%]), PI-RADS 4 (75/250 [30%]; GS  ≥ 7:  n = 64 
[26%]), and PI-RADS 5 (68/96 [71%]; GS  ≥ 7:  n = 57 [60%]). Pa-
tients undergoing first biopsy ( n = 133; lesions  n = 228): PI-
RADS 2: (5/37 [14%]; GS  ≥ 7:  n   = 2 [5%]), PI-RADS 3 (13/74 
[18%]; GS  ≥ 7:  n = 7 [9%]), PI-RADS 4 (34/83 [41%]; GS  ≥ 7:  n = 
27 [33%]), and PI-RADS 5 (26/34 [76%]; GS  ≥ 7:  n = 24 [71%]). 
Patients on active surveillance undergoing control biopsy ( n = 
47; lesions  n = 88): PI-RADS 2: (4/14 [29%]; GS  ≥ 7:  n = 4 [29%]), 
PI-RADS 3 (11/31 [35%]; GS  ≥ 7:  n = 4 [13%]), PI-RADS 4 (9/25 
[36%]; GS  ≥ 7:  n = 7 [28%]), and PI-RADS 5 (10/18 [56%]; GS 
 ≥ 7:  n = 9 [50%]). 
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 Fig. 2. ROC for the detection of clinically 
significant prostate cancer in lesions evalu-
ated according to PI-RADS. 
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was detected. Twenty-three percent (13/56) of lesions 
classified as PI-RADS 3 with evidence of significant PCa 
were associated with another lesion harboring signifi-
cant PCa. Similarly to lesions classified as PI-RADS 2, all 
of these associated lesions were classified as PI-RADS 
 ≥ 4. Thirty-one percent (196/625) of patients presented 
maxPI-RADS 3 lesions. Twenty three of these patients 
presented only PI-RADS 3 lesions (23 lesions) with evi-
dence of significant PCa. In 16 of these patients, signifi-
cant PCa was detected in sysPbx as well, while 7 of these 
patients did not present significant PCa in sysPbx. How-
ever, 12 patients presenting only PI-RADS 3 lesions lack-
ing evidence of significant PCa presented a significant 
PCa in sysPbx. In total, 14% of significant PCa (35/246) 
would not have been detected, if patients with only PI-
RADS 3 lesions would not have undergone either tar-
geted or sysPbx.
 Comparison of maxPI-RADS to the Biopsy Results 
in the Combination of fusPbx and sysPbx: 
A Patient-Based Analysis 
 The detection rates of all and significant PCa in 
 comPbx according to the presented maxPI-RADS are de-
picted in  Table 5 .
 In regression analysis, age, prostate specific antigen 
(PSA)-value, prostate volume, and a maxPI-RADS  ≥ 4 
were predictors for the detection of significant PCa in 
comPbx in uni- and multivariate analyses. In contrast to 
maxPI-RADS  ≥ 3, maxPI-RADS  ≥ 4 was the strongest pre-
dictor for the detection of significant PCa in comPbx 
 ( Table 6 ).
 Discussion 
 In this study, we demonstrated that PI-RADS corre-
lates with the detection of significant PCa in targeted bi-
opsy. Furthermore, we showed that the evidence of max-
PI-RADS  ≥ 4 is significantly associated with the detection 
of significant PCa in comPbx.
 In both lesion- and patient-based analyses, the cancer-
detection rate of significant PCa in lesions classified as 
PI-RADS 4 and 5 was lower than described in the current 
literature. Detection rates of significant PCa of up to 86 
and 93% are reported for PI-RADS 4 and 5 lesions respec-
tively  [12, 13] . In another patient-based analysis (312 pa-
tients, 452 lesions), Rastinehad et al.  [14] showed a detec-
tion rate of 54.4% in PI-RADS 4 and 83.6% in PI-RADS 
5 for significant PCa. Additionally, in a lesion-based anal-
ysis, they showed detection rates of 36.7% in PI-RADS 4 
and 81.8% in PI-RADS 5 for significant PCa.
 Previous studies reported that targeted biopsy alone 
would miss significant PCa in 6–16%  [4, 15] . Our data 
confirmed these results with an overall missing rate of 9% 
for significant PCa in fusPbx alone. Especially in patients 
undergoing repeat biopsy, 12% of significant PCa were 
missed in targeted biopsy.
 Furthermore, our data demonstrated that if patients 
with PI-RADS 2 lesions were not investigated by comPbx, 
7% of significant PCa (17/246) would be missed. Abd-
Alazeez et al.  [16] reported an NPV of 89–100% of  mpMRI 
to exclude significant PCa in patients without any evi-
dence of tumor-suspicious lesions in mpMRI. Similar 
data were published by Wysock et al.  [17] evaluating the 
detection rate of 12-core biopsy in case of a negative 
mpMRI in 75 patients. They showed a detection rate of 
significant PCa of 1.3% in all and of 4% in patients with 
previously negative sysPbx, but no evidence of significant 
PCa in patients undergoing first biopsy or control-biopsy 
in active surveillance protocols. However, in our cohort, 
the detection rate of significant PCa in lesions classified 
as PI-RADS 2 was higher in patients on active surveil-
lance undergoing control biopsy (29%) than that in other 
subgroups (3–9%). Higher detection rates of significant 
PCa in PI-RADS 2 lesions in patients on active surveil-
lance may be explainable by initially higher evidence of 
PCa in this cohort. Almeida et al.  [18] reported a correla-
tion of visible lesions in mpMRI (defined as PI-RADS  ≥ 4) 
and a risk of upstaging in patients eligible for active sur-
veillance but undergoing radical prostatectomy. Addi-
tionally, a negative mpMRI or an mpMRI presenting PI-
RADS 1 or 2 lesions should be interpreted in the context 
of clinical parameters (PSA-value, DRE) and the grade of 
suspiciousness of PCa. In these patients a sysPbx should 
be considered  [10] .
 In our cohort, evidence of at least one lesion classified 
as PI-RADS  ≥ 4 was the strongest independent predictor 
for detection of significant PCa in uni- and multivariate 
Table 5.  Detection rates of PCa in MRI/ultrasound-fusion biopsy 
in combination to systematic biopsy with regard to the maxPI-
RADS
maxPI-RADS All PCa, n (%) Significant PCa, n (%)
≤2 (n = 65) 21 (32) 13 (20)
3 (n = 196) 73 (37) 46 (23)
4 (n = 247) 130 (53) 102 (41)
5 (n = 117) 97 (83) 85 (73)
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analyses. Further independent predictors were higher 
age, higher PSA-value, and smaller prostate volume. Fur-
thermore, our data revealed a specificity of 65%, a low 
PPV of 37%, and an accuracy of 66% for the detection of 
significant PCa defined as GS  ≥ 7 (3 + 4) in lesions classi-
fied as PI-RADS  ≥ 4. However, the high NPV (89%) may 
underline the value of mpMRI as a triage tool for the de-
cision to perform prostate biopsy. Nevertheless, a sensi-
tivity of 72% indicates that mpMRI would still miss sig-
nificant PCa and sysPbx should still be performed. Due 
to the low specificity and PPV in mpMRI, a biopsy is still 
needed in patients presenting with at least one lesion with 
a PI-RADS  ≥ 4. Conversely, in case of a negative biopsy, 
but in the presence of PI-RADS 4 or 5 lesions, mpMRI 
and the performance of targeted biopsy should be reeval-
uated and a close follow-up with targeted rebiopsies 
should be considered  [10] . For this reason, clinical pa-
rameters are still important indicators for evaluating 
the presence of PCa beside the mpMRI findings. More-
over, the inter-reader variability in the interpretation of 
mpMRI should be taken into account. In mpMRI reeval-
uated by experienced radiologists, a down- or upgrading 
of PI-RADS (v1 and v2) up to 35–45% and 13–19% was 
described respectively  [19] . This underlines the necessity 
of achieving high quality and standardization in the per-
formance and interpretation of mpMRI.
 There is consensus to perform targeted biopsy in le-
sions classified as PI-RADS  ≥ 3  [20] . However, the char-
acteristics of PI-RADS 3 lesions are sparsely described. In 
this study, we showed in a lesion-based analysis, that 12% 
of detected PI-RADS 3 lesions harbored significant PCa. 
However, in a patient-based analysis, which evaluates pa-
tients presenting exclusively PI-RADS 3 lesions, 14% of 
significant PCa would be missed if these patients would 
not have undergone comPbx. Liddell et al.  [21] investi-
gated 118 patients presenting 92 PI-RADS 3 lesions out 
of 215 lesions. They described a cancer detection rate in 
PI-RADS 3 lesions of only 6% (6 lesions), whereas only 2 
lesions presented significant PCa. Our data underline 
that the presence of PI-RADS 3 lesions justifies the neces-
sity of targeted biopsy also in combination with sysPbx 
due to a portion of 6% of missed significant PCa if 
only fusPbx were performed in patients presenting max-
PI-RADS 3 lesions. However, targeting PI-RADS 2 le-
sions may be omitted in patients undergoing first or re-
peat biopsy without evidence of PCa in previous biopsy, 
while sysPbx should still be performed due to a high de-
tection rate of significant PCa in 7%.
 The median number of cores taken by comPbx was 19. 
The median number of cores in fusPbx and sysPbx was 7 
and 12 respectively. This total number of cores is compa-
rable to a saturation biopsy with 20–24 cores and above. 
Other study groups perform fusPbx in combination with 
volume-based systematic template biopsy, which results 
in a median number of 20–30 systematic cores, while the 
detection rate of all and significant PCa was comparable 
to our detection rates  [22–24] . However, saturation and 
template biopsy alone still represent a methodology for a 
systematic but blind biopsy, unless there are no hy-
poechogenic lesions detectable in grey-scale ultrasound. 
The advantage of fusPbx is the opportunity to target tu-
mor-suspicious lesions in mpMRI. Recent data have 
shown that targeted fusPbx detects significantly more 
clinically significant PCa with a higher proportion of 
cores testing positive for PCa compared to template or 
saturation biopsy  [25, 26] . Analyses of our data support 
Table 6.  Uni- and multivariate logistic regressions analyses for determination of predictors for the detection of significant prostate can-
cer
Parameter Comparison Univariate regression analysis  Multivariate regression analysis
OR (95% CI) p value OR (95 % CI) p value
Age (median 65a) ≤ vs. > median 1.9 (1.34–2.64) <0.005 2.09 (1.42–3.06) <0.005
First biopsy Yes vs. no 1.3 (0.88–1.91) 0.184
Known PCa Yes vs. no 1.39 (0.77–2.53) 0.279
PSA (median 8.17 ng/mL) ≤ vs. > median 2.37 (1.70–3.29) <0.005 2.39 (1.62–3.53) <0.005
DRE cT1 vs. ≥ cT2 2.01 (1.26–3.201) 0.003 1.69 (0.97–2.94) 0.064
Prostate volume (median 50 mL) ≤ vs. > median 0.22 (0.15–0.32) <0.005 0.21 (0.14–0.31) <0.005
maxPI-RADS ≥3 PI-RADS ≤2 vs. ≥3 2.85 (1.52–5.34) 0.001 1.34 (0.66–2.95) 0.392
maxPI-RADS ≥4 PI-RADS ≤3 vs. ≥4 3.617 (2.54–5.16) <0.005 2.77 (1.81–4.24) <0.005
Significant parameters are depicted in bold.
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the use of mpMRI as well as the currently used reporting 
system (PI-RADS) for the detection of PCa. However, the 
diagnostic accuracy is not sufficiently high to safely omit 
prostate biopsies in patients with lesions classified as PI-
RADS 2 and 3.
 This study had several limitations. First, this study 
evaluated a heterogeneous population regarding demo-
graphic data or prior biopsy history, which may reduce 
the generalization of our results but reflect the daily prac-
tice. Second, approximately one third of our study popu-
lation was evaluated by PI-RADS v2, while for the re-
maining two-thirds of cases PI-RADS v1 was used for 
evaluation of mpMRI. In this study, we did not perform 
a reevaluation according to PIRADS v2 of mpMRIs inves-
tigated by PI-RADS v1 and vice versa. That may have had 
an influence on the detection rate due to the different 
weights of the performed sequences in the evaluation of 
lesions according to the localization in the peripheral and 
transitional zone. Third, targeted and sysPbx were per-
formed subsequently by the same urologist and hence not 
blinded. The knowledge about the location of lesions in 
mpMRI could influence the operator in unintended nee-
dle placement during the sysPbx. This could result in a 
false high detection rate in sysPbx. Finally, because of the 
heterogeneous definition of clinically significant cancer, 
we decided to distinguish mainly between tumors with 
GS 6 and with GS  ≥ 7 (3 + 4) for evaluation of tumor up-
grading of the 2 biopsy modalities.
 In conclusion, PI-RADS correlates with the tumor ag-
gressiveness. In this study, maxPI-RADS is the strongest 
predictor for the detection of significant PCa in comPbx. 
Due to a high detection rate of additional significant PCa 
in sysPbx, fusPbx should still be combined with sysPbx. 
In case of maxPI-RADS 2, targeted biopsy may be omit-
ted and sysPbx should be performed instead.
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